Brought to you by 
QuatRx closes $28mm Series C round
22 Jul 2003
Executive Summary
QuatRx Pharmaceuticals, a start-up biotech company developing treatments for endocrine, metabolic, and cardiovascular diseases, closed a $28mm Series C private placement led by new investor MPM Capital. Another newcomer, InterWest Partners, also participated along with returning investors Frazier Healthcare Ventures and TL Ventures.
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Financing
- Venture Financing
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
QuatRx closes $28mm Series C round
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice